60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Statistics & Valuation Metrics

60 Degrees Pharmaceuticals, Inc. has a market cap or net worth of $4.30M. The enterprise value is -$50.68K.

60 Degrees Pharmaceuticals, Inc. has 2,636,788 shares outstanding. The number of shares has decreased by -2.65% in one year.

60 Degrees Pharmaceuticals, Inc.’s return on equity (ROE) is -2.13 and return on invested capital (ROIC) is -219.65%.

The current PE Ratio of 60 Degrees Pharmaceuticals, Inc. is ―. 60 Degrees Pharmaceuticals, Inc.’s PEG ratio is 0.00219.

In the last 12 months, 60 Degrees Pharmaceuticals, Inc. had revenue of 1.01M and earned -7.37M in profits. Earnings per share was -11.73.

In the last 12 months, operating cash flow was -9.80M and capital expenditures -125.45K, giving a free cash flow of -9.93M billion.

60 Degrees Pharmaceuticals, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

60 Degrees Pharmaceuticals, Inc. upcoming earnings date is May 14, 2026, During Market Hours (Confirmed).

60 Degrees Pharmaceuticals, Inc. as a current ratio of 2.66, with Debt / Equity ratio of 4.41%

In the past 12 months, 60 Degrees Pharmaceuticals, Inc. has paid 0.00 in taxes.

60 Degrees Pharmaceuticals, Inc. EV to EBITDA ratio is >-0.01, with an EV/FCF ratio of >-0.01.

60 Degrees Pharmaceuticals, Inc. has $2.75M in cash and marketable securities with $152.78K in debt, giving a net cash position of $2.60M billion.

Gross margin is 22.26%, with operating margin of -771.64%, and net profit margin of -732.82%.

The average price target for 60 Degrees Pharmaceuticals, Inc. is $14.10, which is 11.43% higher than the current price. The consensus rating is Moderate Buy